危险分层
医学
头颈部
头颈部癌
推论
肿瘤科
癌症
内科学
计算生物学
生物
外科
计算机科学
人工智能
作者
Clemens P. Spielvogel,Stefan Stoiber,László Papp,Denis Krajnc,Marko Grahovac,Elisabeth Gurnhofer,Karolína Trachtová,Vojtěch Bystrý,Asha Leisser,Bernhard J. Jank,Julia Schnoell,Lorenz Kadletz,Gregor Heiduschka,Thomas Beyer,Marcus Hacker,Lukas Kenner,Alexander Haug
标识
DOI:10.1007/s00259-022-05973-9
摘要
Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population.In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC.Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone.Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI